Опыт включения Гамавита и Фоспренила в схему терапии гемоплазмоза кошек для повышения эффективности коррекции анемии – ретроспективный анализ

Abstract

This study includes clinical data collected from 2016 to 2023. In total, hemoplasmosis was detected in 102 cats (63 females and 39 males) aged from 5 months to 8 years. Of these, 34 cats were diagnosed with a severe form of the disease, and 68 with a mild one. In cats with severe hemoplasmosis, in 45 % of cases, the disease was complicated by chronic renal failure. Also, 5 % of them were chronic carriers of toxoplasmas. Most of the animals were taken from shelters, or were homeless. One of the leading clinical signs of hemoplasmosis is anemia, which develops as a result of mass hemolysis of infected red blood cells. The aim of this work was to eliminate anemia and accelerate the normalization of hematopoiesis in cats with hemoplasmosis. For the treatment of 45 animals (control group), a standard therapy regimen was used, which included antibiotics and glucocorticoids, whereas for therapy regimen of remaining 57 cats (experimental group) Gamavit and Phosprenyl were added. Using this therapeutic scheme, early relief of anemia, stimulation of erythropoiesis, restoration of blood formula and normalization of liver function were noted as well as acceleration of clinical recovery of sick animals which occurred faster by 4…5 days.